

DEPARTMENT OF HEALTH & HUMAN SERVICES
Centers for Medicare & Medicaid Services
7500 Security Boulevard, Mail Stop S2-14-26
Baltimore, Maryland 21244-1850



Disabled & Elderly Health Programs Group

April 12, 2013

Jennifer Velez
Commissioner
Division of Medical Assistance and Health Services
P.O. Box 712, Mail Code #1
Trenton, NJ 08625-0712

Dear Ms. Velez:

We have reviewed the New Jersey State Plan Amendment (SPA) 13-02 received in the New York Regional Office on February 25, 2013. The State of New Jersey proposes to discontinue covering claims for dual eligible beneficiaries when prescribed barbiturates for the treatment of epilepsy, cancer or a chronic mental health disorder and benzodiazepines for all indications as Medicare Part D will provide this coverage effective January 1, 2013. Based on the information provided, we are pleased to inform you that SPA 13-02 is approved with an effective date of January 1, 2013.

A copy of the CMS-179 form, with the pen and ink changes authorized by the state at box seven, as well as the pages approved for incorporation into the state plan will be forwarded by the New York Regional Office. If you have any questions regarding this amendment, please contact Madlyn Kruh at (410) 786-3239.

Sincerely,

/ s /

Larry Reed
Director
Division of Pharmacy

cc: Michael Melendez, ARA, New York Regional Office
Ivelisse Salce, New York Regional Office
Julie Hubbs – New Jersey DMAHS Regulatory Officer

DEPARTMENT OF HEALTH & HUMAN SERVICES
Centers for Medicare & Medicaid Services
New York Regional Office
26 Federal Plaza, Room 37-100
New York, NY 10278



DIVISION OF MEDICAID AND CHILDREN'S HEALTH OPERATIONS

April 12, 2013

Ms. Jennifer Velez, Commissioner
Division of Medicaid Assistance and Health Services
P.O. Box 712, Mail Code #1
Trenton, New Jersey 08625-0712

Dear Ms. Velez:

We received a copy of Larry Reed's letter to you, in which he notified you of the approval of New Jersey's State Plan Amendment (SPA) 13-02. The State of New Jersey proposes to discontinue covering claims for dual eligible beneficiaries when prescribed barbiturates for the treatment of epilepsy, cancer or a chronic mental health disorder and benzodiazepines for all indications as Medicare Part D will provide this coverage effective January 1, 2013.

Mr. Reed advised you that the New York Regional Office would forward you the signed CMS-179 form as well as copy of the approved page, these documents are enclosed. The revised page of addendum to attachment 3.1-A submitted to our office on March 26, 2013 has replaced the corresponding page that was originally into the New Jersey state plan. Please note the approval date of the SPA is April 12, 2013 and the effective date is January 1, 2013.

If you have any questions, please contact Ivelisse M. Salce at (212) 616-2411.

Sincerely,

A handwritten signature in black ink, appearing to read "Michael Melendez". The signature is fluid and cursive, with a long horizontal line extending to the right.

Michael Melendez
Associate Regional Administrator
Division of Medicaid and Children's Health

Cc. Madlyn Kruh, CMS Division of Pharmacy
Julie Hubbs, New Jersey DMAHS Regulatory Officer